Background: With the recent increased awareness of youth-onset type 2 diabetes (T2D) cases, an overview of national differences in epidemiology data is needed to obtain a global picture of the disease development.

Methods and Aim: This review examined national epidemiology data of youth-onset T2D published between 1st January 2008 and 15th January 2018, and searched for national guidelines on this topic to understand better national similarities and differences.

Results: Of the 1005 articles and 14 congress abstracts identified, 42 studies were included. The highest reported prevalence rates of youth-onset T2D were found in the U.S. and China (38 and 18 cases/100,000 people, respectively), and lowest in Denmark and Ireland (0.6 and 1.2 cases/100,000 people, respectively) (Figure). However, the highest incidence rates were reported in Taiwan and the UK (63 and 33 cases/100,000 people, respectively), with the lowest in Fiji and Austria (0.4 and 0.6 cases/100,000 people, respectively) (Figure). These differences may be partly explained by variations in diagnostic criteria, national screening recommendations, and ethnicity within countries.

Conclusions: Our review suggests that published national epidemiology data for youth-onset T2D may underestimate its disease burden. Finding optimal diagnostic criteria and screening strategies for this disease should be of high interest to every country.


J.L. Lynch: Board Member; Self; American Academy of Pediatrics. Consultant; Self; Novo Nordisk Inc. Research Support; Self; Daiichi Sankyo Company, Limited, National Institutes of Health, Novo Nordisk Inc., Pediatric Diabetes Consortium. M. Barrientos-Pérez: Advisory Panel; Self; Novo Nordisk A/S. Research Support; Self; Eli Lilly and Company, Novo Nordisk A/S, Sanofi. Speaker's Bureau; Self; Pfizer Inc. M. Hafez: Advisory Panel; Self; Merck & Co., Inc. Consultant; Self; Global Expert Panel for T2 diabetes. M. Jalaludin: Advisory Panel; Self; Merck Sharp & Dohme Corp., Novo Nordisk A/S. Research Support; Self; Merck Sharp & Dohme Corp., Novo Nordisk A/S. M. Kovarenko: Advisory Panel; Self; Novo Nordisk Pediatric Type 2 Diabetes Global Expert Panel. Speaker's Bureau; Self; Berlin-Chemie AG, LifeScan, Inc., Medtronic, Novo Nordisk A/S, Sanofi. V. Paturi: Advisory Panel; Self; Novo Nordisk Foundation. Board Member; Spouse/Partner; DiabetOmics Inc., DiabetOmics Inc. Board Member; Self; DiabetOmics Medical. Consultant; Self; Ramdevrao Hospital. Employee; Self; DiabetOmics Medical. Research Support; Self; Eli Lilly and Company, Hetero Pharma, Ipca Laboratories Ltd., IQVIA, Novo Nordisk A/S, Quintiles, RSSDI (Research Society for the Study of Diabetes in India), Sanofi. Speaker's Bureau; Self; Novo Nordisk A/S. Stock/Shareholder; Self; DiabetOmics Inc. D. Weghuber: Advisory Panel; Self; Novo Nordisk A/S. Speaker's Bureau; Self; Johnson & Johnson.


Novo Nordisk A/S

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at